Evidence map›Paper›PMID 25481284›Full record

ArticleVirus research2015

Controlled viral glycoprotein expression as a safety feature in a bivalent rabies-ebola vaccine.

Amy B Papaneri, John G Bernbaum, Joseph E Blaney, Peter B Jahrling, Matthias J Schnell, Reed F Johnson

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Virus research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Multivalent and Multipathogen Viral Vector Vaccines.Clinical and vaccine immunology : CVI · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Amy B PapaneriNIH/NIAID, Ft. Detrick, MD, USA.
John G BernbaumNIH/NIAID, Ft. Detrick, MD, USA.
Joseph E BlaneyNIH/NIAID, Ft. Detrick, MD, USA.
Peter B JahrlingNIH/NIAID, Ft. Detrick, MD, USA.
Matthias J SchnellNIH/NIAID, Ft. Detrick, MD, USA.
Reed F JohnsonNIH/NIAID, Ft. Detrick, MD, USA. Electronic address: johnsonreed@mail.nih.gov.
National Institutes of Health · US

Funding

Pathogenesis and countermeasures of poxviruses, hemorrhagic fever viruses, MERSZIAAI001025 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI JOHNSON, REED · 2009 to 2018
$14.1M
Preclinical characterization of a multivalent killed Filovirus/Rabies vaccineR01AI105204 · NIAID · THOMAS JEFFERSON UNIVERSITY · PI SCHNELL, MATTHIAS JOHANNES · 2013 to 2017
$5.0M
Intramural NIH HHS Z99 AI999999Intramural NIH HHS ZIA AI001025NIAID NIH HHS HHSN272200700016INIAID NIH HHS R01 AI105204PHS HHS 272200700016I
6 · The paper itself

Abstract

Using a recombinant rabies (RABV) vaccine platform, we have developed several safe and effective vaccines. Most recently, we have developed a RABV-based ebolavirus (EBOV) vaccine that is efficacious in nonhuman primates. One safety feature of this vaccine is the utilization of a live but replication-deficient RABV construct. In this construct, the RABV glycoprotein (G) has been deleted from the genome, requiring G trans complementation in order for new infectious viruses to be released from the initial infected cell. Here we analyze this safety feature of the bivalent RABV-based EBOV vaccine comprised of the G-deleted RABV backbone expressing EBOV glycoprotein (GP). We found that, while the level of RABV genome in infected cells is equivalent regardless of G supplementation, the production of infectious virus is indeed restricted by the lack of G, and most importantly, that the presence of EBOV GP does not substitute for G. These findings further support the safety profile of this replication-deficient RABV-EBOV bivalent vaccine.

Indexed as

Gene ExpressionAnimalsAntigens, ViralEbola VaccinesGene DeletionGenetic Complementation TestGlycoproteinsHemorrhagic Fever, EbolaPrimatesRabiesRabies VaccinesRecombinant ProteinsVaccines, AttenuatedVaccines, SyntheticViral Envelope ProteinsAntigens, ViralEbola Vaccinesenvelope glycoprotein, Ebola virusglycoprotein G, Rabies virusGlycoproteinsRabies VaccinesRecombinant ProteinsVaccines, AttenuatedVaccines, SyntheticViral Envelope ProteinsBiodefenseEbolaFilovirusRabies virusRNA virusesVaccine

Identifiers

PMID25481284
PMCPMC4362543
OpenAlexW1992919779

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.